Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 12/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001731 | 0.92 | MAP3K14 (0.34) | MAP3K14CNR2 | |
| SCHEMBL12001608 | 0.90 | MAP3K14 (0.34) | MAP3K14CNR2RORC | |
| SCHEMBL11970731 | 0.87 | MAP3K14 (0.46) | MAP3K14 | |
| SCHEMBL12001646 | 0.86 | MAP3K14 (0.37) | MAP3K14CNR2CNR1 | |
| SCHEMBL12001711 | 0.86 | MAP3K14 (0.34) | MAP3K14TRPV1 | |
| SCHEMBL12001528 | 0.81 | MAP3K14 (0.31) | MAP3K14 | |
| SCHEMBL11970812 | 0.79 | MAP3K14 (0.48) | MAP3K14 | |
| SCHEMBL12001472 | 0.79 | TTBK1 (0.36) | MAP3K14ALOX5AP | |
| SCHEMBL11970643 | 0.77 | MAP3K14 (0.47) | MAP3K14 | |
| SCHEMBL11970530 | 0.73 | MAP3K14 (0.48) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885CNR2 749/4885TRPV1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.